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Abstract
Background: Severe mental illnesses (SMI) may be independently associated with cardiovascular
risk factors and the metabolic syndrome. We aimed to systematically assess studies that compared
diabetes, dyslipidaemia, hypertension and metabolic syndrome in people with and without SMI.
Methods: We systematically searched MEDLINE, EMBASE, CINAHL & PsycINFO. We hand
searched reference lists of key articles. We employed three search main themes: SMI,
cardiovascular disease, and each cardiovascular risk factor. We selected cross-sectional, case
control, cohort or intervention studies comparing one or more risk factor in both SMI and a
reference group. We excluded studies without any reference group. We extracted data on: study
design, cardiovascular risk factor(s) and their measurement, diagnosis of SMI, study setting,
sampling method, nature of comparison group and data on key risk factors.
Results: Of 14592 citations, 134 papers met criteria and 36 were finally included. 26 reported on
diabetes, 12 hypertension, 11 dyslipidaemia, and 4 metabolic syndrome. Most studies were cross
sectional, small and several lacked comparison data suitable for extraction. Meta-analysis was
possible for diabetes, cholesterol and hypertension; revealing a pooled risk ratio of 1.70 (1.21 to
2.37) for diabetes and 1.11 (0.91 to 1.35) of hypertension. Restricting SMI to schizophreniform
illnesses yielded a pooled risk ratio for diabetes of 1.87 (1.68 to 2.09). Total cholesterol was not
higher in people with SMI (Standardized Mean Difference -0.10 (-0.55 to 0.36)) and there were
inconsistent data on HDL, LDL and triglycerides with some, but not all, reporting lower levels of
HDL cholesterol and raised triglyceride levels. Metabolic syndrome appeared more common in
SMI.
Conclusion: Diabetes (but not hypertension) is more common in SMI. Data on other risk factors
were limited by poor quality or inconsistent research findings, but a small number of studies show
greater prevalence of the metabolic syndrome in SMI.
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Background
People with severe mental illness (SMI) such as schizo-
phrenia and bipolar affective disorder are at greater risk of
coronary heart disease (CHD) than people without such
diagnoses [1-3]. The mutable risk factors for CHD are
smoking, hypertension, diabetes mellitus and high ratio
of total cholesterol to High Density Lipoprotein (HDL)
cholesterol. Although, many people with SMI are likely to
be heavy smokers, and less likely to succeed in smoking
cessation [4], the relationship between SMI and CHD
mortality is not wholly explained by smoking[3] and
there has been increasing interest in the prevalence of dia-
betes and dyslipidaemia in people with SMI. Second gen-
eration antipsychotics may exacerbate features of the
metabolic syndrome including abnormal glucose and
lipid profiles [2,5,6]. But recent reviews have suggested
that people with SMI are at risk of the metabolic syn-
drome including diabetes irrespective of antipsychotic
therapy [7,8]. People with SMI share other risk factors
including unhealthy lifestyles [9] obesity and positive
family histories [10].
We hypothesised that there were differences in the risk of
abnormal glucose, blood pressure or lipid abnormalities
between people with and without SMI. We searched for
studies comparing the risk of diabetes or hyperglycaemia,
hypertension, dyslipidaemia or a combination of these
factors (as components of the metabolic syndrome or as
an overall CHD risk score). We did not aim to assess
smoking since a systematic review has recently been pub-
lished [4] and the conclusions are uncontroversial.
Methods
We searched for studies of diabetes or hyperglycaemia,
hypertension, dyslipidaemia or combinations of these
factors in people with and without SMI and systematically
reviewed the literature to appraise the epidemiological
evidence. We estimated the strength of any association
between SMI and these CHD risk factors.
Data sources and search strategy
We electronically searched MEDLINE, EMBASE, CINAHL,
the Cochrane Library database & PsycINFO for articles in
English, French, German, Italian or Spanish and sought
papers published between 1897 and 2005 inclusively. We
hand searched reference lists of review papers and made
contact with authors and researchers to ensure compre-
hensive coverage. We piloted and modified our search
strategy to retrieve all key papers in this field. The most
sensitive search included three broad search themes
namely 1) Terms related to SMI, 2) cardiovascular dis-
eases and 3) the risk factors of diabetes, lipid disorders,
hypertension, the metabolic syndrome and cardiovascular
risk scores. Synonym lists were constructed for each theme
and the databases were searched using these synonyms as
both thesaurus and free-text terms (Additional file 1). For
SMI, we included all terms relating to psychotic disorders,
schizophreniform disorders, bipolar affective disorders
and psychotic depression. Similarly all synonyms for
search themes 2 and 3 were employed. We included an
additional wider term for all mental disorders in a final
search combined with both search themes 2 and 3. A com-
bination of these two approaches provided the most reli-
able results.
Study selection
We included cross sectional, case-control, cohort and
intervention studies in which the risk factors of interest
were available in a group with SMI and a reference group
without SMI. We excluded pharmacological studies com-
paring CHD risk factors between different antipsychotics
and without any comparison data from people not pre-
scribed these drugs as these studies could not shed light
on comparative risk between people with and without
SMI. We included all studies involving representative
groups with SMI and noted whether they were sampled
from the community; outpatient settings, inpatients or
from long stay psychiatric accommodation.
Screening process
Two or more authors independently read all titles and
available abstracts to identify potentially relevant articles.
Decisions were compared and disagreements were dis-
cussed at steering group meetings involving all authors.
We translated non-English articles to determine their rele-
vance.
Data extraction
We extracted data on the type of study design, the setting
and the source of the groups with and without SMI. We
recorded the type and method of SMI diagnosis and the
reported response rate. We extracted which CHD risk fac-
tors (e.g. diabetes) were reported and how they were
measured and defined. We noted whether all participants
were screened for CHD risk or whether the outcome (e.g.
diabetes) relied on screening and diagnosis being made
during routine clinical care. Summary data (i.e. raw num-
bers and percentages) on the prevalence of risk factors
were obtained for each group including raw numbers and
percentages. Comparative statistics were noted including
absolute differences in continuous outcomes or propor-
tions and estimates of relative risk such as odds ratios.
Adjustment of main results for confounders was also
noted.
Data synthesis
We defined three levels of evidence. The highest level were
studies where a non-SMI comparison group was recruited.
The next level were those that did not recruit a compari-
son group but used comparative risk factors data fromBMC Psychiatry 2008, 8:84 http://www.biomedcentral.com/1471-244X/8/84
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general health population studies and the lowest level
included studies where a selected group with other psychi-
atric diagnoses was used as a comparison. Within these
levels we then grouped studies according to SMI diagno-
sis, and the sampling frame for the SMI group(e.g. com-
munity or from a specific secondary care setting such as an
inpatient unit or clinic. Finally, where possible we calcu-
lated summary statistics such as risk ratios (RRs), confi-
dence intervals and standardized mean differences (the
mean difference in outcome/standard deviation for out-
come; the effect size) for outcomes even when the papers
had not presented such results. This was only possible
when papers either reported raw numbers for dichoto-
mous outcomes or means plus standard deviations for
continuous outcomes.
Meta-analysis
Data were entered into Stata version 9 [11] and standard
meta-analytic techniques were employed if there were
more than three studies for a given outcome. Meta-analy-
ses could only conducted on studies that reported data
from a comparison group. We calculated pooled estimates
of effect sizes and risk ratios using a random effects model
that uses inverse variance methods to apportion more
weight to larger rather than smaller studies in the meta-
analysis. We approached heterogeneity in results between
studies in two ways. Firstly we assessed whether a signifi-
cant level of difference existed using Mantel-Haenszel chi
square tests. If the chi square test was significant below p
= 0.05, we quantified the amount of heterogeneity using
I2 statistics. We considered I2 above 50% as an indicative
of substantial heterogeneity.
Where studies only reported percentages, we could only
calculate risk ratios rather than odds ratios. For consist-
ency we therefore present risk ratios rater than odds ratios
in the meta-analyses.
Results
The initial database search generated 14592 papers, 134
papers were identified for further scrutiny but more
detailed assessment by up to four authors yielded 36
papers [12-47] that were eligible for inclusion in the final
review (figure 1).
27 papers reported outcomes related to diabetes or hyper-
glycemia, 14 reported hypertension or blood pressure, 12
dyslipidaemia or lipid levels, 5 the metabolic syndrome
and 4 papers included overall cardiovascular risk scores
such as a ten year Framingham risk score [48]. Of the 98
excluded papers, the most common reason for ineligibil-
ity was that the paper only explored specific comparisons
between different antipsychotic drugs, without compari-
son data on people not taking the drugs (n = 23). Many
studies reported cardiovascular outcomes in samples of
people with SMI without any reference data (n = 38). In
several studies, samples included people with multiple
diagnoses other than our definition of SMI (such as
dementia), with no specific data for the subgroups with
SMI as defined in this paper. Other reasons for ineligibil-
ity can be viewed in figure 1.
Study characteristics
Of the 36 papers included, most (28/36) reported cross
sectional data on one or more cardiovascular risk factors.
There were 8 papers utilizing data from longitudinal stud-
ies [14-16,18,20,35,39,44], although strictly, none col-
lected consecutive longitudinal information regarding
cardiovascular risk factors at both baseline and follow-up.
Four studies [12,13,33,45] recruited specifically from
community settings, eight studies [14-16,24,25,37,46,47]
from a mixture of outpatient and inpatient settings, and 5
studies [22,23,34,42,43] from outpatient clinics. The
remaining 19 studies collected data from acute or long
stay inpatient samples. These papers are summarized in
additional file 2; tables 1–5, by outcome of diabetes/
hyperglycaemia (additional file 2; table 1), hypertension/
blood pressure (additional file 2; table 2), dyslipidaemia/
lipid levels (additional file 2; table 3), metabolic syn-
drome (additional file 2; table 4) and 10 year CHD risk
scores (additional file 2; table 5). Within these tables, the
studies are grouped according to whether they recruited a
comparison group or simply used general population
data, and by source of the SMI sample (eg inpatients or
community).
Diabetes and hyperglycaemia
Twenty seven eligible papers [12-36,46,47] reported glu-
cose related outcomes (additional file 2; table 1). The
location of the studies, source, definition, SMI diagnosis
and relevant outcomes for each study are summarized in
additional file 2; table 1. Diabetes or hyperglycemia defi-
nitions included diagnosis or treatment for diabetes in the
clinical records (n = 17) [12-18,22,24-27,30,34-36,46]
self-reported diabetic diagnosis (n = 2) [23,25], screening
results for random glucose (n = 2)[13,29] or fasting glu-
cose(n = 3) [20,28,47] and impaired glucose tolerance (n
= 3) [19,31,32]. Most studies (n = 23) included people
with diagnoses of schizophrenia and/or schizoaffective
disorder, two studies also included people with bipolar
affective disorder [27,46]. Three studies only included
people with a diagnosis of bipolar disorder [26,30,35].
Nine studies provided data that could be used in the meta-
analysis for diabetes [12-16,18-20,23] (figure 2).
These studies involved 9612 people with SMI, 1166 of
whom had a diagnosis of diabetes and a total of 3449677
people without SMI of whom 534248 had recognized dia-
betes. The pooled risk ratio for diabetes in SMI was 1.70BMC Psychiatry 2008, 8:84 http://www.biomedcentral.com/1471-244X/8/84
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Flowchart of search results and studies included in final review Figure 1
Flowchart of search results and studies included in final review.
Broad database searches 
14592 papers i tified  den
  Initial screening based on titles/abstracts
Potentially relevant to CVD Risk Factor 
review 
199 papers 
   
Data Papers 
N = 109 
Review Papers 
N = 90 
Hand searching of  
reference lists 
Papers identified from hand 
searching references/expert 
opinion
N = 25 
Total papers considered for data 
extraction 
N = 134 
Excluded: N = 98
Reasons for exclusion: 
No comparison group (n=38); solely 
antipsychotic-focused/ drug-specific data 
without comparison (n=23); no relevant 
prevalence data or mean values (n=21); 
non-SMI people in main sample (n=13); SMI 
also in comparison group (n=1); outside 
adult age range (n=1); study excluded 
cases where risk factor present, introducing 
bias (n=1) 
Data extracted from paper 
N = 36 
Diabetes (n = 27); Hypertension (n = 14); Dyslipidemia (n = 12);     
Metabolic Syndrome (n = 5); Framingham Risk Score (n = 4) BMC Psychiatry 2008, 8:84 http://www.biomedcentral.com/1471-244X/8/84
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(1.21 to 2.37). There was considerable heterogeneity with
a significant overall test for heterogeneity (chi square =
57.91 p < 0.001; I2 = 91.2%). However, within the schizo-
phrenia and/or schizoaffective disorder group there was
no significant heterogeneity (p = 0.837, I2 < 0.1%). In this
group risk ratios for recorded diabetes ranged from 0.54 to
9.0 and the pooled risk ratio was 1.87 (1.68 to 2.09). The
derived risk ratio from the one study including partici-
pants with bipolar affective disorder was 1.10 (1.03 to
1.18). There was no significant difference in results from
studies of inpatient SMI samples compared to community
samples (test for heterogeneity between subgroups p =
0.851).
Figure 3 displays risk ratios for diabetes in SMI and, where
possible, confidence intervals (exact figures in additional
file 2; table 1). These are based on studies in which the
data were unsuitable for inclusion in meta-analysis (e.g.
comparison data only reported as percentages or using
general population statistics without raw data).
Four studies compared random[13] or fasting[19,20,47]
glucose levels, of which two [13,20] showed significantly
increased standardized mean differences in the SMI
group. The CATIE study [47] reported mixed results which
differed by gender. Mean fasting glucose was significantly
raised in SMI females but not males. However males with
SMI were significantly more likely to reach criteria for
raised fasting glucose than controls but this finding was
not repeated in females (additional file 2; table 1)
Hypertension
Fifteen papers reported data relating to hypertension
(additional file 2; table 2). Most included people with
schizophrenia or schizoaffective disorder but three papers
included people with bipolar affective disorder
Random Effects Meta-Analysis on Risk Ratios of Diabetes Prevalence between those with schizophrenia or Bipolar Disorder  and a control group Figure 2
Random Effects Meta-Analysis on Risk Ratios of Diabetes Prevalence between those with schizophrenia or 
Bipolar Disorder and a control group.
Diabetes
  Risk ratio
 .02  1  160
 Study
  Risk ratio
 (95% CI)
 Schizophrenia
 Makikyro et al (1998)   0.75 ( 0.05, 12.04)
 Dickerson et al (2002)   1.90 ( 0.70, 5.16)
 Ryan et al (2003)   9.00 ( 0.51, 159.15)
 Curkendall et al (2004)   1.82 ( 1.58, 2.08)
 Sokal et al (2004)   1.77 ( 0.96, 3.23)
 Enger et al (2004)   2.00 ( 1.62, 2.46)
 Saari et al (2005)   0.54 ( 0.03, 8.50)
 Osborn et al (2006)   3.50 ( 1.06, 11.58)
 Subtotal   1.87 ( 1.68, 2.09)
 Bipolar
 Kilbourne et al (2004)   1.10 ( 1.03, 1.18)
 Subtotal   1.10 ( 1.03, 1.18)
 Overall   1.70 ( 1.21, 2.37)BMC Psychiatry 2008, 8:84 http://www.biomedcentral.com/1471-244X/8/84
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P[16,38,46]. Hypertension was variously assessed by: self-
report, existing use of anti-hypertensive medication, diag-
nosis of hypertension in clinical records, direct measure-
ment of blood pressure and use of varying systolic and
diastolic thresholds for hypertension (additional file 2;
table 2).
Seven studies that included 2333/6249 people with SMI
who were hypertensive and 1261228/2169371 hyperten-
sive people without SMI were included in the meta-analy-
sis and none showed significantly elevated risk for
hypertension in the SMI group (figure 4). The pooled risk
ratio for hypertension in SMI was 1.11 (0.91 to 1.35). Het-
erogeneity was significant (Chi square test p < 0.001 I2 =
89.2%).
We were able to calculate risk ratios (but not confidence
intervals) for hypertension from four further studies
which also reported general population comparison data,
resulting in two raised RRs [23,38] and two reduced RRs
[34,46] for hypertension in SMI (additional file 2; table
2).
Dyslipidaemia
12 studies reported a variety of lipid outcomes including
total cholesterol, High Density Lipoprotein (HDL) choles-
terol and Low Density Lipoprotein (LDL) cholesterol and
triglycerides (additional file 2; table 3), some using fasting
samples and some not. Seven included raw data from a
comparison group, and only three studies included peo-
ple with bipolar affective disorder. The only lipid out-
come reported in sufficient studies for meta-analysis was
mean total cholesterol (figure 5). Total cholesterol values
were available for 160 people with SMI and 5702 people
without SMI in 4 different studies [13,19,39,40] The
pooled SMD was -0.10 (0.55 to 0.36) (figure 5). There was
Risk Ratios for Diabetes comparing those with Schizophrenia, Bipolar disorder or SMI with a comparison group Figure 3
Risk Ratios for Diabetes comparing those with Schizophrenia, Bipolar disorder or SMI with a comparison 
group. Studies not suitable for inclusion in metaanalysis.
Mixed SMI
Bipolar
Schizophrenia or
Schizo-Affective
Disorder
SCZ
SCZ-AFF
18-44yrs
45-64yrs
vs depression
vs osteoarthritis
Lilliker et al, 1980
Regenold et al, 2002
Kessing et al, 2004
Kessing et al, 2004
Mukherjee et al, 1996
Steinert et al, 1996
Casadebaig et al, 1997
Cassidy et al, 1999
Dixon et al, 2000
Dixon et al, 2000
Regenold et al, 2002
Regenold et al, 2002
Cohen et al, 2003
Subramaniam et al, 2003
Gierz & Jeste, 2004
Lamberti et al, 2004
Chafetz et al, 2005
Hung et al, 2005
Susce et al, 2005
S
t
u
d
y
.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6BMC Psychiatry 2008, 8:84 http://www.biomedcentral.com/1471-244X/8/84
Page 7 of 14
(page number not for citation purposes)
significant heterogeneity; (chi square = 14.91, p = 0.002;
I2 = 79.9%) with one study showing an SMI group with
lower total mean cholesterol and another showing SMI
the opposite result.
Standardized mean differences between SMI and non-SMI
samples could be calculated for HDL cholesterol, LDL
cholesterol and triglycerides in two studies [13,19]
(figure 6).
One of these studies found significantly lower HDL levels
and higher triglyceride levels [13]. The other found signif-
icantly lower LDL levels [19] (figure 6).
Some studies also reported lipid results based on: a diag-
nosis of hyperlipidaemia or lipid disorders (by ICD crite-
ria) [14,16] receipt of antilipemic medication[14], or
proportions of people with lipid levels exceeding a
defined threshold [13,20,47]. These results were incon-
sistent. In some studies people with SMI were significantly
more likely to have low HDLP[13,47] high triglycer-
ides[20,47] or a high HDL/total cholesterol ratio but in
others these did not reach significance for either HDL[20]
and LDL levels[13] or total cholesterol [13]. A calculated
risk ratio for prevalence of ICD 9 dyslipidaemic disorders
was not significant (0.86: 0.73 to 1.01) [14].
Studies with insufficient data for calculating SMDs, or
where other patient groups were used for comparison,
also reported conflicting results. SMI was associated with
significantly lower total cholesterol in one study[36] with
significantly lower HDL cholesterol in others [37,47] but
this was not confirmed elsewhere[39]. Triglyceride results
were also inconsistent [39,41,47].
Random Effects Meta-analysis of Risk Ratio for prevalence of Hypertension between those with Schizophrenia, Bipolar or SMI  and a Comparison Group Figure 4
Random Effects Meta-analysis of Risk Ratio for prevalence of Hypertension between those with Schizophrenia, 
Bipolar or SMI and a Comparison Group.
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 89.2%, p = 0.000)
Schizophrenia
Subtotal  (I-squared = 90.2%, p = 0.000)
Study
Bipolar Disorder
Subtotal  (I-squared = .%, p = .)
Saari et al (2005)
McEvoy et al (2005)
Chafetz et al (2005)
Steinert et al (1996)
ID
Kilbourne et al (2004)
Osborn et al (2006)
Curkendall et al (2004)
Sokal et al (2004)
1.11 (0.91, 1.35)
1.17 (0.85, 1.61)
0.94 (0.91, 0.98)
1.19 (0.83, 1.72)
1.57 (1.37, 1.81)
1.31 (0.90, 1.92)
2.00 (0.62, 6.41)
RR (95% CI)
0.94 (0.91, 0.98)
0.95 (0.45, 1.99)
0.82 (0.74, 0.90)
1.05 (0.74, 1.50)
1.11 (0.91, 1.35)
1.17 (0.85, 1.61)
0.94 (0.91, 0.98)
1.19 (0.83, 1.72)
1.57 (1.37, 1.81)
1.31 (0.90, 1.92)
2.00 (0.62, 6.41)
RR (95% CI)
0.94 (0.91, 0.98)
0.95 (0.45, 1.99)
0.82 (0.74, 0.90)
1.05 (0.74, 1.50)
1 .1 1 7BMC Psychiatry 2008, 8:84 http://www.biomedcentral.com/1471-244X/8/84
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Metabolic syndrome
Five papers involving 1026 people with schizophrenia or
schizoaffective disorder reported prevalence of the meta-
bolic syndrome according to international criteria, but
only two studies used raw data from a comparison group
in addition to 718 people with schizophrenia [20,47]
(additional file 2; table 4). The other three studies used
general population comparison data that were not suita-
ble for meta-analysis (due to a lack of raw numbers) and
not clearly age matched to the people with SMI. Figure 7
displays risk ratios (and where possible calculated confi-
dence intervals) from all five studies. All point estimates
for risk of the metabolic syndrome were raised.
Ten year cardiovascular risk scores
Four studies report ten year cardiovascular risk scores for
people with SMI, two included comparison groups
[13,44], and two used general population comparison
data [37,45] (additional file 2; table 5). In two studies,
involving 352 people with SMI, the 10 year cardiovascular
risk scores was significantly increased in men but not
women with SMI [37,45]. One study of 21 first-onset
cases of schizophreniform illnesses showed significantly
raised 10 year risk scores compared to general population,
but no differences compared to matched controls [44].
Finally, one controlled community study found that
excess cardiovascular risk scores were only detectable
when different effects were considered at different age
groups [13].
Discussion
We found that diabetes mellitus is the cardiovascular risk
factor most convincingly associated with SMI. Meta-analy-
sis of the highest quality studies revealed almost a two-fold
risk of diabetes in schizophrenia-like illnesses but not bipo-
lar affective disorder. Conversely, meta-analysis revealed no
association between SMI and hypertension. Similar find-
ings were observed for total cholesterol levels, but these
studies were limited by their design and so conclusions
must be guarded. There were inadequate numbers of com-
parative studies of other lipids, such as HDL cholesterol, or
of the metabolic syndrome to conduct a meta-analyses.
Lower HDL cholesterol levels in people with SMI found in
two studies [13,47] were not confirmed by another [20].
Random effects Meta Analysis of Studies reporting total cholesterol results for those with SMI and those without Figure 5
Random effects Meta Analysis of Studies reporting total cholesterol results for those with SMI and those with-
out.
 
Total Cholesterol
 Standardised mean difference
 -1  0  1
 Study
 Standardised mean difference
 (95% CI)
 McCreadie et al (2000)  -0.41 (-0.92, 0.10)
 Ryan et al (2003)  -0.69 (-1.25,-0.13)
 Saari et al (2004)   0.46 ( 0.10, 0.81)
 Osborn et al (2006)   0.08 (-0.20, 0.36)
 Overall  -0.10 (-0.55, 0.36)
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Five studies on the metabolic syndrome revealed an excess
risk in people with SMI, and two, involving 718 people
with SMI, confirmed such an excess of metabolic syndrome
statistically. Raised "Framingham" or ten year cardiovascu-
lar risk scores may only be demonstrable in SMI when dif-
ferences in effects are examined separately in different age
groups and sexes. For instance excess risk scores may only
be detectable in those over 40.
Quality and variability of published studies
There were very few high quality comparative studies on
cardiovascular risk factors and the metabolic syndrome in
people with and without SMI. Many studies in this review
were limited by small, convenience samples of people
with SMI such as those in specific clinics or inpatient
units, compromising the generalisability of their findings.
Furthermore, several studies reporting higher levels of car-
diovascular risk in SMI did not obtain raw comparison
data within their study to allow statistical assessment of
the importance of their findings. Cardiovascular risk fac-
tors are increasing rapidly in the general population,
hence the need for relevant contemporary comparison fig-
ures. There were no studies designed to compare the lon-
gitudinal development of cardiovascular risk factors
between people with and without SMI.
The meta-analysis for diabetes did not detect any hetero-
geneity between inpatient and community samples with
schizophreniform illnesses, suggesting consistency
between settings despite the sampling bias inherent to
inpatient samples. However the result for people with
bipolar disorder was significantly different from that for
schizophrenia (figure 2). The marked heterogeneity score
from the hypertension meta-analysis suggested that there
was considerable variation between studies which may
have arisen from the differing sampling methods and/or
different definitions of hypertension employed in differ-
ent papers.
Plot of Standardised Mean Difference between those with Schizophrenia and a control group for HDL, LDL and Triglycerides Figure 6
Plot of Standardised Mean Difference between those with Schizophrenia and a control group for HDL, LDL 
and Triglycerides.
HDL
LDL
Triglycerides
Osborn et al, 2006
Ryan et al, 2003
Osborn et al, 2006
Ryan et al, 2003
Osborn et al, 2006
Ryan et al, 2003
S
t
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Based on our second level of evidence, (namely studies
utilizing general population figures for comparison data)
the estimated excess risk of diabetes varied between a zero
and a fivefold risk (figure 3). Only three of these studies
permitted calculation of confidence intervals for diabetes
risk ratios and two of these were not significant at the 5%
level (figure 3). This wide variation in the magnitude of
diabetes risk between studies may reflect differences in 1)
the sampling and definition of SMI, 2) the source of the
comparison group (and their inherent risk for diabetes),
and 3) the definition of diabetes or hyperglycemic out-
comes. Furthermore, studies that rely on identification of
cardiovascular risk factors in routine clinical practice may
be flawed due to differential screening rates in people with
and without SMI. In the past, people with SMI may have
been less likely to be screened for diabetes. More recently
there is evidence that people prescribed certain second
generation antipsychotics are more likely to receive
screening for diabetes. The direction of bias due to differ-
ential screening rates may therefore extend in either direc-
tion, leading to underestimation or overestimation of
diabetes prevalence in SMI, compared to people without.
This review included several small studies that may have
lacked statistical power to detect real differences in risk
factors or the metabolic syndrome. Few studies have
investigated effect modification by age, but there is some
support of this phenomenon when comparing people
with and without SMI [3,13].
Strengths and limitations
This is the first review to systematically appraise quality
and synthesise data from comparative studies of diabetes,
hypertension and lipid levels in people with and without
SMI.
We paid critical attention to the quality of studies, in
terms of the representativeness of samples, the outcomes
Risk Ratios for Metabolic Syndrome comparing those with Schizophrenia, SMI or Bipolar disorder to a control group or gen- eral population Figure 7
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measured and we present a large volume of comparative
results regarding the prevalence of cardiovascular risk in
SMI.
We have grouped these studies according to levels of qual-
ity within additional file 2; tables 1–5, especially regard-
ing their selection of comparison data and where possible
explored the role of different diagnoses and sampling
methods in the meta-analysis. There were insufficient
papers to allow us to further subdivide the results.
The review was labour intensive, and like other systematic
reviews there was inevitably a delay between the search
and publication of the review. The search strategy
retrieved over 14,000 papers. However narrowing the
search terms was not acceptable because the restricted
search missed several important papers of which we were
aware.
Therefore, during the production of this review further
evidence may have emerged subsequent to our original
search. From our knowledge of the field we are aware of
one quality paper meeting our criteria involving both SMI
and controls which was published in 2007. Mackin et al
[49] reported data consistent with the main findings of
this review. They compared metabolic parameters in 90
people with severe mental illnesses and 92 without. They
report increased rates of cardiovascular risk factors in SMI
including impaired glucose metabolism, lower HDL cho-
lesterol and raised LDL cholesterol, raised triglycerides
and increased metabolic syndrome. In common with our
findings, blood pressure was not raised in this study [49].
These recent results have not been included in our analy-
sis because this would bias the systematic nature of our
review. Legitimate inclusion of this paper would require
re-running of the search for other papers from 2007 and
reviewing potentially thousands of new titles. This would
be beyond the scope of our current funding.
We acknowledge the difficulty of synthesizing data from
multiple studies. In this field many existing studies of car-
diovascular risk factors have been opportunistic and have
not ensured their SMI samples are representative nor that
comparison data are comparable in terms of ethnicity and
socio-economic deprivation. This may further explain the
observed variation in results and heterogeneity. Further-
more several papers which are commonly cited as evi-
dence for increased cardiovascular risk in SMI could not
be included as they contained insufficient data or no com-
parison data.
In particular, studies that rely on clinical diagnoses for
outcome definition are problematic, since many people
may have cardiovascular risk which is undetected (such as
abnormal lipids). Screening for lipids, blood pressure and
glucose probably occurs in less than a third of people with
SMI during routine practice [50]. These points may
explain why other narrative reviews conclude the risk of
diabetes may be even higher in people with SMI [7,8].
A further challenge is the employment of different defini-
tions of outcomes such as diabetes, hypertension and
metabolic syndrome in different studies. We minimised
this problem by only including papers which compare
risks in people with and without SMI using the same def-
inition, thus focusing on the relative rather than absolute
risk. The relative risk is less sensitive to the employment of
differing definitions.
The poor epidemiological quality of studies in this field
has been highlighted by a complementary systematic
review [51] examining the relative diabetogenic risk of
first and second generation antipsychotics. The authors
found methodological weaknesses in most studies and
were only able to make tentative conclusions about the
possible role of second generation antipsychotics in the
aetiology of diabetes.
Explanation of excess risk
No studies longitudinally assessed predictors of diabetes
(or other cardiovascular risk factors) in SMI. The relative
contribution of second generation antipsychotics [2,4,6],
lifestyle[10], family history [10], social deprivation and
SMI itself (perhaps through chronic stress models) are still
debated [7]. This possible role of SMI itself is supported
by two small studies suggesting metabolic disturbances
may be observable in newly diagnosed or drug naïve peo-
ple with SMI [52,53]. However our findings reveal that we
do not have an accurate estimate of the contribution of
either second generation antipsychotics or SMI itself, to
support or refute these theories. We know that the relative
risk of metabolic harm differs between the second gener-
ation antipsychotics [2,4,6,10] but the absolute attributa-
ble risks are unclear.
To understand excess cardiovascular disease in SMI we
must improve our knowledge of cardiovascular risk fac-
tors in two areas. First, we must accurately determine the
extent of the excess of diabetes, dyslipidaemia, hyperten-
sion and the metabolic syndrome in representative sam-
ples of people with and without SMI, taking into account
the effects of age, gender and socio-economic status. This
can be achieved in studies with adequate comparison data
that explore the level of risk apportionable to SMI and to
relevant confounders, especially socio-economic status
[13]. Secondly, to determine the risk attributable to antip-
sychotic medication, lifestyle, stress and addictions to car-BMC Psychiatry 2008, 8:84 http://www.biomedcentral.com/1471-244X/8/84
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diovascular risk we require data from carefully designed
prospective studies. Retrospective estimates of such expo-
sures in SMI are limited by inaccurate reporting and recall
bias. Finally, these studies should be adequately powered
and should test specific mechanistic hypotheses, rather
than measuring multiple risk factors.
Conclusion
Our findings emphasise the importance of poor physical
health outcomes in people with SMI, including adverse
cardiovascular outcomes. However, we have highlighted
gaps in our current knowledge base. This review suggests
that diabetes is indeed more common in SMI. Metabolic
syndrome may also be more common, while there is far
weaker evidence regarding dyslipidaemia and hyperten-
sion. We require high quality studies in representative
samples of people with SMI in which all participants have
been screened for cardiovascular risk. These should be
cross-referenced to contemporary comparison data
regarding the incidence of risk factors in the general pop-
ulation. Furthermore studies should explore differences in
risk factors at different ages and require the statistical
power to do so.
The mechanism underlying adverse cardiovascular out-
comes remains poorly understood and it is premature to
quantify the roles of antipsychotic medication, social
adversity, psychiatric symptoms, physiological stress,
smoking and diet on the causal pathway of cardiovascular
diseases.
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